Abstract
Background and Objectives: The clinical use of cyclophosphamide-doxorubicin (CP-DOX) in breast cancer treatment may cause hepatotoxicity. This study assessed the protective effect of alpha-lipoic acid (ALA) against hepatotoxicity induced by CP-DOX in albino rats. Materials and Methods: Thirty-six adult male albino rats were randomized into six groups (A-F) of n = 6. Group A (control) was treated intraperitoneally (ip) with 0.3 mL of normal saline 8 hourly for 48h. Group B was treated with 10 mg/kg of ALA 8 hourly ip for 48 h. Group C was treated with a dose of CP-DOX (150/20 mg/kg) for 24 h. Group D was pre-treated with ALA 8 hourly for 48 h before treatment with a dose of CP-DOX ip for 24h. Group E was co-treated with a dose of CP-DOX and ALA ip 8 hourly for 48 h. Group F was treated with a dose of CP-DOX for 24 h before treatment with ALA ip 8 hourly for 48 h. After treatment, rats were euthanized; blood samples were collected and evaluated for serum liver function markers. Liver samples were evaluated for biochemical markers and histology. Results: Liver catalase, superoxide dismutase, glutathione (GSH), and GSH peroxidase levels were significantly (P
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
